These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30286224)

  • 21. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB; Bastholt L; Yderstræde K
    Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.
    Albayda J; Bingham CO; Shah AA; Kelly RJ; Cappelli L
    Rheumatology (Oxford); 2018 Apr; 57(4):760-762. PubMed ID: 29342300
    [No Abstract]   [Full Text] [Related]  

  • 26. Checkpoint Inhibitor-Induced Colitis.
    Bellaguarda E; Hanauer S
    Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
    Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
    Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
    Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
    Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 35. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins.
    Spänkuch I; Gassenmaier M; Tampouri I; Noor S; Forschner A; Garbe C; Amaral T
    Eur J Cancer; 2017 Aug; 81():203-205. PubMed ID: 28641200
    [No Abstract]   [Full Text] [Related]  

  • 38. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
    Menzies AM; Pires da Silva I; Trojaniello C; Vieu E; Amaria RN; Zimmer L; Lo SN; Burton EM; Tawbi HA; Schadendorf D; Grob JJ; Ascierto PA; Long GV
    N Engl J Med; 2022 Apr; 386(17):1668-1669. PubMed ID: 35476655
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunotherapy in colorectal cancer with mismatch repair deficiency.
    Overman MJ
    Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
    [No Abstract]   [Full Text] [Related]  

  • 40. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.